Consumption of antidiabetic medicines in Portugal: results of a temporal data analysis of a thirteen‐year study (2005–2017)

Table 1 The consumption of antidiabetic drugs in DDD/TID, from the second ATC level to the fourth ATC level, between 2005 and 2017

ATC	Medicines	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
ATC	Medicines	DDD/TID
A10	Antidiabetics	49.3	52.3	55.4	60.8	64.6	67.8	70.2	73.6	78.9	82.2	84.4	86.0	88.2
A10A	Insulins and analogues	5.3	6.9	7.7	8.6	9.2	10.1	10.9	11.8	13.1	13.9	14.4	15.0	15.4
A10B	Non-insulin antidiabetics	44.0	45.4	47.7	52.2	55.4	57.7	59.3	61.7	65.8	68.3	69.9	71.0	72.9
A10A	Insulins and analogues
A10AB	Fast-acting insulins	1.0	0.9	1.2	1.6	1.9	2.2	2.6	3.0	3.4	3.7	3.9	4.1	4.3
A10AC	Intermediate-acting insulins	3.0	3.1	3.5	3.5	3.1	3.0	2.7	2.5	2.4	2.4	2.3	2.1	2.0
A10AD	Combined-acting insulins	1.4	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1	2.9	2.8	2.6
A10AE	Long-acting insulins	< 0.1	< 0.1	< 0.1	0.5	1.1	1.8	2.6	3.3	4.1	4.8	5.3	5.9	6.4
A10B	Non-insulin antidiabetics
A10BA	Biguanides	12.8	13.5	14.9	17.4	18.0	17.7	18.0	19.2	20.9	22.1	22.6	23.0	23.1
A10BB	Sulphonylureas	24.9	23.7	23.2	22.3	21.0	19.7	18.5	18.8	19.2	18.8	17.8	16.7	15.8
A10AF	α-glucosidase inhibitors	3.4	3.3	3.2	3.0	2.7	2.4	2.1	1.9	1.7	1.5	1.2	1.0	0.8
A10BG	Glitazones	0.2	0.2	0.6	1.0	1.0	1.1	1.1	1.0	0.9	0.8	0.6	0.5	0.5
A10BH	DPP-4 inhibitors	-	-	> 0.1	2.4	3.6	3.8	4.1	4.4	4.9	5.6	6.1	6.5	6.8
A10BJ	GLP-1 analogues	-	-	-	-	-	-	-	-	-	0.3	0.8	1.0	1.2
A10BK	SGLT2 inhibitors	-	-	-	-	-	-	-	-	-	< 0.1	1.0	2.0	3.0
A10BX	Other non-insulin antidiabetics	0.3	0.5	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.2	0.2
A10BD	Oral fixed-dose combinations	2.4	4.1	5.1	5.3	8.5	12.4	15.0	16.0	17.9	18.9	19.5	20.3	21.4

Note: The results presented in Table 1 were rounded to the first decimal place. The authors performed all calculations with raw data. Therefore, calculating annual growth rates with Table 1 data may lead to slightly different results than those presented in the text of this article

ISSN: 1472-6823